Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUT00063 in age-related hearing loss
NCT02345031Phase 2Completed
- Sponsor
- Autifony Therapeutics
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related hearing loss comparing AUT00063 with Placebo (2 arms). Primary endpoint: Quick Speech-in-Noise Test at 28 days. Started Jan 2015; status: completed.
02
Drugs
AUT00063
03
Conditions
age-related hearing loss
Beyond the preview
Go deeper on NCT02345031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345031.